Navigation Links
Healthmed Neural Communicator Final Phase Test Results Exceed Expectations

SUNNYVALE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Healthmed Services, Ltd. (OTC QB: HEME), an innovative software and application development company, is in the final phases of beta testing its Neural Vantage communicator. 

The Company is in the final phase of testing its neural communicator on a voluntary group of disabled individuals with special needs.  These tests are being conducted in military medical establishments and voluntary patient houses. Final phase test results have exceeded all expectations and  the Company believes its products will be available to paralyzed and amputee patients later this year. Healthmed's line of Neural Communication products has been designed to bridge the technological information and communication gap between physically impaired individuals and virtually all aspects of computing, which has become a day to day activity for all of us.

Healthmed CFO Dale Paisley, stated "This line of products will not only serve as the bridge between disabled individuals and vital communication, but also serves a plethora of other "touchless" applications in addition to increasing the quality of life for the severely disabled."

"The Company has learned this product can be modified to meet specialized needs of patients. It is our goal to continue building products of this type to assist all individuals with communication challenges."

You may read more about the Company and its product developments on its website:

Notice Regarding Forward-Looking Statements 

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. 

SOURCE Healthmed Services Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
2. HealthMedia and Aetna to Study Online Insomnia and Depression Interventions
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. Neuralstem Announces Issuance of Core Technology Patent in Europe
5. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
6. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
9. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
10. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
11. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
Post Your Comments:
(Date:11/30/2015)... 30, 2015   Nuance Communications, Inc. (NASDAQ: ... Support Company (NDSC) today jointly announced a new ... that utilize the American College of Radiology,s (ACR) Imaging ... to comply with current and emerging value-based payment ... --> By combining clinical decision support, radiology reporting ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting a ... for a child’s exposure limits. , The original Nov 2015 CR story titled, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, a ... Radiology Society of North America (RSNA) annual meeting, being held November 29 – ... 2014. Throughout 2015, the company has completed installations for Integrated Delivery Network ...
(Date:11/30/2015)... , ... November 30, 2015 , ... It’s inevitable that ... family member, close friend, or animal pass away, death lives among us. It is ... , Coming from a family of 11 children, author T Sky understands that she ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... ... 2015 , ... Scott Newman MD, FACS of New York’s ... surgeons in the New York City area to utilize the new, non-invasive SculpSure™ ... laser treatment for fat loss in the abdomen, flanks, and other areas that ...
Breaking Medicine News(10 mins):